11:07 AM EDT, 08/15/2024 (MT Newswires) -- (Corrects misspelling of Medicare in the headline.)

Novo Nordisk ( NVO ) submitted a notice of appeal to the US Court of Appeals for the Third Circuit after a federal district judge rejected its arguments against the Medicare Drug Price Negotiation Program.

The appeal was filed one day before the Centers for Medicare & Medicaid Services published the first 10 negotiated drug prices under the new program.

Price: 136.72, Change: +2.30, Percent Change: +1.71